Views Navigation

Today

The Science Behind the Substance

Webinar , Canada

A Microsoft Teams webinar with cannabinoid clinic educators outlining the potential applications of medical cannabis through the exploration of the endocannabinoid system (ECS). It will also discuss the implications of alterations in the ECS and how supplementing with phytocannabinoids may be beneficial for ameliorating symptoms. The latest research into ‘minor’ cannabinoids such as CBN will […]

Dosed 2-Encore Presentation

The Vic Theatre Victoria, British Columbia, Canada

Back by popular demand-an encore presentation of ‘Dosed 2: The Trip of a Lifetime’ featuring a cameo role in the movie followed by moderating a panel discussion on cannabinoid along with psychedelic therapy. This documentary revolves around the story of a patient using psychedelics to assist in her final transition while saying goodbye to friends […]

Medical Cannabis and Polypharmacy-Reducing the Risks

Laurel Point Inn Victoria, British Columbia, Canada

A combination live streaming webinar followed by an in-person meeting to discuss the potential role that medical cannabis may play in reducing the overall pill burden for many patients. Polypharmacy can lead to multiple side effects along with serious drug interactions that are responsible for significant morbidity and hospitalizations. This interactive discussion will address the […]

The Science Behind the Substance-Exploring Cannabis Options

Webinar , Canada

A Microsoft Teams webinar with cannabinoid clinic educators outlining the potential applications of medical cannabis through the exploration of the endocannabinoid system (ECS). It will also discuss the implications of alterations in the ECS and how supplementing with phytocannabinoids may be beneficial for ameliorating symptoms. The latest research into ‘minor’ cannabinoids such as CBN will […]

Medical Cannabis and Parkinson’s Disease

Zoom webinar

Interactive Zoom lecture for the Parkinson's Society of Southern Ontario. Discussion of various aspects to be considered when determining whether medical cannabis would be a suitable option in the management of Parkinson’s Disease (PD) symptoms. This presentation will include the history of cannabis for therapeutic purposes including a review of the science, description of cannabinoids, […]

The Role of Medical Cannabis in a Harm Reduction Strategy

Kelowna, BC

In-person conference with key opinion leaders to discuss options such as cannabinoid therapy in an effort to help manage addictions to various substances including opiates, alcohol and tobacco.

Green is the New Grey-Seniors and Medical Cannabis

Mary Winspear Center Sidney, BC, Canada

In person presentation as part of the University of Victoria Continuing Education lecture series. This interactive event will review the history of medical cannabis along with discussing the science of the endocannabinoid system and how integral it is in the understanding of how cannabis may provide options in managing various conditions. As well, this talk […]

Exploring the Science Behind Medical Cannabis

Zoom webinar

An interactive Zoom webinar with cannabinoid clinic educators outlining the potential applications of medical cannabis through the exploration of the endocannabinoid system (ECS). It will also discuss the implications of alterations in the ECS and how supplementing with phytocannabinoids may be beneficial for ameliorating symptoms. The latest research into 'minor' cannabinoids such as CBN will […]

Medical Cannabis in Harm Reduction-Video Podcast

Podcast

Taping of virtual podcast for future social media platforms regarding the potential utilization of cannabinoids as a novel substitute in the reduction of polypharmacy along with opiate medications.

Medical Cannabis as a Novel Substitute in a Harm Reduction Strategy

Arcadian Court 401 Bay Street, Toronto, Ontario, Canada

In-person presentation at a Canadian Harm Reduction Conference in Toronto, Ontario highlighting the potential benefits of utilizing medical cannabis as a novel contribution in battling the opioid crisis along with reduction of polypharmacy.